Announcements Trials
Browse Landscape

Phase

Phase 2 55Phase 1 34Phase 1/2 23Phase 3 11Phase 2/3 5Phase EARLY_PHASE1 3Phase 4 2

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1CNS 1

Conditions

Melanoma 2Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 8Nivolumab 8Biopsy 7Radiotherapy 6Temozolomide 4Specimen Handling 4Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Surgical Procedures, Operative 3Paclitaxel 3Leukapheresis 3Ipilimumab 3Fluorodeoxyglucose F18 3Aspirin 3perflutren 2alovudine 2Tirzepatide 2Rituximab 2Positron-Emission Tomography 2Phantoms, Imaging 2Omeprazole 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Immunotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ipilimumab × 90 days × Clear all
NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
104 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT05498792 2026-05-22

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Fox Chase Cancer Center

Phase EARLY_PHASE1 Recruiting
12 enrolled
Dermatologic

Melanoma

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡